159 related articles for article (PubMed ID: 38672622)
41. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.
Wang B; Shen C; Li Y; Zhang T; Huang H; Ren J; Hu Z; Xu J; Xu B
Onco Targets Ther; 2019; 12():5751-5765. PubMed ID: 31410021
[No Abstract] [Full Text] [Related]
42. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract][Full Text] [Related]
43. β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial-Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling.
Cao ZQ; Wang XX; Lu L; Xu JW; Li XB; Zhang GR; Ma ZJ; Shi AC; Wang Y; Song YJ
Front Pharmacol; 2018; 9():1525. PubMed ID: 30670971
[TBL] [Abstract][Full Text] [Related]
44. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer.
Martinez MJ; Lyles RDZ; Peinetti N; Grunfeld AM; Burnstein KL
iScience; 2023 Sep; 26(9):107681. PubMed ID: 37705955
[TBL] [Abstract][Full Text] [Related]
46. LncRNA SNHG6 Upregulates KPNA5 to Overcome Gemcitabine Resistance in Pancreatic Cancer via Sponging miR-944.
Gao G; Li X; Wu H; Huang LL; Lin YX; Huo Z; Xiang ZY; Zhou X
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259332
[TBL] [Abstract][Full Text] [Related]
47. Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer.
Yang Y; Gu H; Zhang K; Guo Z; Wang X; Wei Q; Weng L; Han X; Lv Y; Cao M; Cao P; Huang C; Qiu Z
BMC Cancer; 2023 Aug; 23(1):789. PubMed ID: 37612627
[TBL] [Abstract][Full Text] [Related]
48. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract][Full Text] [Related]
49. USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2.
Cui J; Guo Y; Yin T; Gou S; Xiong J; Liang X; Lu C; Peng T
Biomed Pharmacother; 2023 Oct; 166():115359. PubMed ID: 37639742
[TBL] [Abstract][Full Text] [Related]
50. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
[TBL] [Abstract][Full Text] [Related]
51. Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells
Zhu J; Ji Y; Yu Y; Jin Y; Zhang X; Zhou J; Chen Y
Oncol Lett; 2018 Jun; 15(6):8761-8769. PubMed ID: 29805615
[TBL] [Abstract][Full Text] [Related]
52. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer.
Tuerhong A; Xu J; Wang W; Shi S; Meng Q; Hua J; Liu J; Zhang B; Yu X; Liang C
Surgery; 2024 May; 175(5):1264-1275. PubMed ID: 38302326
[TBL] [Abstract][Full Text] [Related]
53. SMYD2 Imparts Gemcitabine Resistance to Pancreatic Adenocarcinoma Cells by Upregulating EVI2A.
Jin L; Qian D; Tang X; Huang Y; Zou J; Wu Z
Mol Biotechnol; 2023 Oct; ():. PubMed ID: 37812330
[TBL] [Abstract][Full Text] [Related]
54. Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer.
Li L; Zhao SL; Yue GGL; Wong TP; Pu JX; Sun HD; Fung KP; Leung PC; Han QB; Lau CBS; Leung PS
Phytomedicine; 2018 May; 44():56-64. PubMed ID: 29895493
[TBL] [Abstract][Full Text] [Related]
55. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
56. Visualization research on ENT1/NIS dual-function gene therapy to reverse drug resistance mediated by MUC1 in GEM-resistant pancreatic cancer.
Xi Y; Chen H; Xi Y; Hai W; Qu Q; Zhang M; Li B
Nucl Med Biol; 2023; 120-121():108350. PubMed ID: 37229950
[TBL] [Abstract][Full Text] [Related]
57. LncRNA MACC1-AS1 induces gemcitabine resistance in pancreatic cancer cells through suppressing ferroptosis.
Zhu J; Yu Z; Wang X; Zhang J; Chen Y; Chen K; Zhang B; Sun J; Jiang J; Zheng S
Cell Death Discov; 2024 Feb; 10(1):101. PubMed ID: 38413579
[TBL] [Abstract][Full Text] [Related]
58. Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells.
Lin L; Liu X; Yu H; Deng H; Peng K; Chen J; Zhang C; Jiang T; Liu X
Front Pharmacol; 2023; 14():1134895. PubMed ID: 36937854
[No Abstract] [Full Text] [Related]
59. Girdin Knockdown Increases Gemcitabine Chemosensitivity to Pancreatic Cancer by Modulating Autophagy.
Wang S; Feng W; Wang W; Ye X; Chen H; Yu C
Front Oncol; 2021; 11():618764. PubMed ID: 33854963
[TBL] [Abstract][Full Text] [Related]
60. BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation.
Zhu LJ; Pan Y; Chen XY; Hou PF
Oncol Lett; 2020 May; 19(5):3506-3512. PubMed ID: 32269624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
